Wingspire Capital provides $40 Million Senior Secured Credit Facility to Theragenics Corporation

ATLANTA – NOV. 10, 2021 — Wingspire Capital LLC (“Wingspire”) is pleased to announce a $40 million senior secured credit facility provided to Theragenics Corporation, a developer and manufacturer of innovative medical devices.

The transaction included a $20 million revolving line of credit and a $20 million term loan, with the proceeds used to refinance existing debt and fund ongoing working capital and general corporate needs.

Now in its 40th year in business, Theragenics is a global leader in the manufacture and sale of brachytherapy “seeds” to treat prostate and other cancers. The Buford, Georgia-based company has also expanded into the manufacture and sale of products for interventional radiology, interventional cardiology, vascular surgery and wound closure. Theragenics product development capabilities focus on oncology and interventional markets.

“Wingspire Capital worked closely with the leadership team at Theragenics to understand their debt structure, working capital and corporate finance goals, and we created a senior secured credit facility that meets their exact needs,” said David Wisen, Founder & CEO of Wingspire Capital.

Frank Tarallo, CEO of Theragenics, commented, “Wingspire developed an understanding of our business, and provided a customized credit facility designed to support our strategic goals and objectives. Wingspire is an important strategic partner for Theragenics as we look forward to our future growth.”

ABOUT WINGSPIRE CAPITAL

Wingspire Capital is a middle market-focused, specialty finance firm